Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5921_Библиотеки_им_академика_М_И_Перельмана
.pdf
76.
McFarland EJ, et al. Live respiratory syncytial virus attenuated by M2-2
deletion and stabilized temperature sensitivity mutation 1030s is a promising
vaccine candidate in children. J Infect Dis. 2020;221(4):534–43.
[PubMed]
77.
McFarland EJ, et al. Live-attenuated respiratory syncytial virus vaccine with
M2-2 deletion and with small hydrophobic noncoding region is highly
immunogenic in children. J Infect Dis. 2020;221(12):2050–9.
[PubMed][PubMedCentral]
78.
Verdijk P, et al. First-in-human administration of a live-attenuated RSV vaccine
lacking the G-protein assessing safety, tolerability, shedding and
immunogenicity: a randomized controlled trial. Vaccine. 2020;38(39):6088–95.
[PubMed]
79.
An X, et al. Single-dose intranasal vaccination elicits systemic and mucosal
immunity against SARS-CoV-2. iScience. 2021;24(9):103037.
[PubMed][PubMedCentral]
80.
van Doremalen N, et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination
reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical
models. Sci Transl Med. 2021;13(607):eabh0755.
81.
Fischer RJ, et al. ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against
SARS-CoV-2 B.1.351 and B.1.1.7. Nat Commun. 2021;12(1):5868.
[PubMed][PubMedCentral]
82.
Cokaric Brdovcak M, et al. ChAdOx1-S adenoviral vector vaccine applied
intranasally elicits superior mucosal immunity compared to the intramuscular
route of vaccination. Eur J Immunol. 2022;52(6):936–45.
[PubMed][PubMedCentral]
83.
Madhavan M, et al. Tolerability and immunogenicity of an intranasallyadministered adenovirus-vectored COVID-19 vaccine: an open-label partiallyrandomised ascending dose phase I trial. EBioMedicine. 2022;85:104298.
[PubMed][PubMedCentral]
84.
Feng L, et al. An adenovirus-vectored COVID-19 vaccine confers protection
from SARS-COV-2 challenge in rhesus macaques. Nat Commun.
2020;11(1):4207.
[PubMed][PubMedCentral]
https://t.me/medicina_free
85.
Xu F, et al. Safety, mucosal and systemic immunopotency of an aerosolized
adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques. Emerg
Microbes Infect. 2022;11(1):438–41.
[PubMed][PubMedCentral]
86.
Kim E, et al. A single subcutaneous or intranasal immunization with
adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular
immune responses in mice. Eur J Immunol. 2021;51(7):1774–84.
[PubMed][PubMedCentral]
87.
Wu S, et al. Safety, tolerability, and immunogenicity of an aerosolised
adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults:
preliminary report of an open-label and randomised phase 1 clinical trial.
Lancet Infect Dis. 2021;21(12):1654–64.
[PubMed][PubMedCentral]
88.
Zhu F, et al. Safety and immunogenicity of a live-attenuated inluenza virus
vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, doubleblind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med.
2022;10(8):749–60.
[PubMed][PubMedCentral]
89.
Kar S, et al. Oral and intranasal vaccines against SARS-CoV-2: current progress,
prospects, advantages, and challenges. Immun Inlamm Dis. 2022;10(4):e604.
[PubMed][PubMedCentral]
90.
Dhama K, et al. COVID-19 intranasal vaccines: current progress, advantages,
prospects, and challenges. Hum Vaccin Immunother. 2022;18(5):2045853.
[PubMed][PubMedCentral]
91.
Miteva D, et al. Mucosal COVID-19 vaccines: risks, beneits and control of the
pandemic. World J Virol. 2022;11(5):221–36.
[PubMed][PubMedCentral]
92.
Chavda VP, et al. Intranasal vaccines for SARS-CoV-2: from challenges to
potential in COVID-19 management. Drug Discov Today. 2021;26(11):2619–36.
[PubMed][PubMedCentral]
93.
Focosi D, Maggi F, Casadevall A. Mucosal vaccines, sterilizing immunity, and the
future of SARS-CoV-2 virulence. Viruses. 2022;14(2):187.
94.
Wollsching-Strobel M, et al. Evolution of web-based training videos provided
by the German respiratory league for the correct inhalation technique.
https://t.me/medicina_free
Respiration. 2022;101(8):757–65.
[PubMed]
95.
Park HJ, et al. Video education versus face-to-face education on inhaler
technique for patients with well-controlled or partly-controlled asthma: a
phase IV, open-label, non-inferiority, multicenter, randomized, controlled trial.
PLoS One. 2018;13(8):e0197358.
[PubMed][PubMedCentral]
96.
Puah SH, et al. Mobile device: a useful tool to teach inhaler devices to
healthcare professionals. BMC Med Educ. 2022;22(1):238.
[PubMed][PubMedCentral]
97.
Press VG, et al. Effectiveness of virtual vs in-person inhaler education for
hospitalized patients with obstructive lung disease: a randomized clinical trial.
JAMA Netw Open. 2020;3(1):e1918205.
[PubMed][PubMedCentral]
98.
Harpaz R, et al. Signaling COVID-19 vaccine adverse events. Drug Saf.
2022;45(7):765–80.
[PubMed][PubMedCentral]
99.
Husby A, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis:
population based cohort study. BMJ. 2021;375:e068665.
[PubMed]
100.
Li C, et al. Intravenous injection of coronavirus disease 2019 (COVID-19)
mRNA vaccine can induce acute Myopericarditis in mouse model. Clin Infect
Dis. 2022;74(11):1933–50.
[PubMed]
101.
Rzymski P, Perek B, Flisiak R. Thrombotic thrombocytopenia after COVID-19
vaccination: in search of the underlying mechanism. Vaccines (Basel).
2021;9(6):559.
102.
McLenon J, Rogers MAM. The fear of needles: a systematic review and metaanalysis. J Adv Nurs. 2019;75(1):30–42.
[PubMed]
103.
Freeman D, et al. Injection fears and COVID-19 vaccine hesitancy. Psychol Med.
2023;53(4):1185–95.
[PubMed]
https://t.me/medicina_free
104.
Bouya S, et al. Global prevalence and device related causes of needle stick
injuries among health care workers: a systematic review and meta-analysis.
Ann Glob Health. 2020;86(1):35.
[PubMed][PubMedCentral]
105.
Hosseinipalangi Z, et al. Global, regional and national incidence and causes of
needlestick injuries: a systematic review and meta-analysis. East Mediterr
Health J. 2022;28(3):233–41.
[PubMed]
106.
Wang YC, et al. Respiratory care for the critical patients with 2019 novel
coronavirus. Respir Med. 2021;186:106516.
[PubMed][PubMedCentral]
107.
Viana Martins CP, Xavier CSF, Cobrado L. Disinfection methods against SARSCoV-2: a systematic review. J Hosp Infect. 2022;119:84–117.
[PubMed]
108.
Hasija V, et al. Environmental impact of COVID-19 vaccine waste: a perspective
on potential role of natural and biodegradable materials. J Environ Chem Eng.
2022;10(4):107894.
[PubMed][PubMedCentral]
109.
Friebel C, Steckel H. Single-use disposable dry powder inhalers for pulmonary
drug delivery. Expert Opin Drug Deliv. 2010;7(12):1359–72.
[PubMed]
110.
de Boer AH, Hagedoorn P. The role of disposable inhalers in pulmonary drug
delivery. Expert Opin Drug Deliv. 2015;12(1):143–57.
[PubMed]
111.
Hasija V, et al. The environmental impact of mass coronavirus vaccinations: a
point of view on huge COVID-19 vaccine waste across the globe during ongoing
vaccine campaigns. Sci Total Environ. 2022;813:151881.
[PubMed]
112.
Rayhan MRI, Liza JM, Rahman MM. Assessment of COVID-19 vaccinationrelated medical waste management practices in Bangladesh. PLoS One.
2022;17(8):e0273053.
[PubMed][PubMedCentral]
113.
Emami F, et al. Drying technologies for the stability and bioavailability of
biopharmaceuticals. Pharmaceutics. 2018;10(3):131.
https://t.me/medicina_free
114.
Sharma A, et al. Innovative drying technologies for biopharmaceuticals. Int J
Pharm. 2021;609:121115.
[PubMed]
115.
Kanojia G, et al. Developments in the formulation and delivery of spray dried
vaccines. Hum Vaccin Immunother. 2017;13(10):2364–78.
[PubMed][PubMedCentral]
116.
Gomez M, Vehring R. Spray drying and particle engineering in dosage form
design for global vaccines. J Aerosol Med Pulm Drug Deliv. 2022;35(3):121–38.
[PubMed]
117.
AboulFotouh K, Cui Z, Williams RO 3rd. Next-generation COVID-19 vaccines
should take eficiency of distribution into consideration. AAPS PharmSciTech.
2021;22(3):126.
[PubMed]
118.
Lee YH, et al. Vaccine-related errors in reconstitution in South Korea: a national
physicians’ and nurses’ survey. Vaccines (Basel). 2021;9(2):117.
119.
Samad F, et al. Strategies to reduce errors associated with 2-component
vaccines. Pharmaceut Med. 2021;35(1):1–9.
[PubMed]
120.
Shastay A. Administering just the diluent or one of two vaccine components
leaves patients unprotected. Home Healthc Now. 2016;34(4):218–20.
[PubMed]
121.
Sheng WH, et al. Safety and antibody response of recipients who unexpectedly
received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan. J
Formos Med Assoc. 2023;122(1):78–81.
[PubMed]
122.
Hassan AO, et al. A single-dose intranasal Chad vaccine protects upper and
lower respiratory tracts against SARS-CoV-2. Cell. 2020;183(1):169–184 e13.
[PubMed][PubMedCentral]
123.
Song X, et al. Aerosolized Intratracheal inoculation of recombinant protective
antigen (rPA) vaccine provides protection against inhalational Anthrax in
B10.D2-Hc(0) mice. Front Immunol. 2022;13:819089.
[PubMed][PubMedCentral]
124.
Mettelman RC, Allen EK, Thomas PG. Mucosal immune responses to infection
and vaccination in the respiratory tract. Immunity. 2022;55(5):749–80.
https://t.me/medicina_free
[PubMed][PubMedCentral]
125.
Duan W, Croft M. Control of regulatory T cells and airway tolerance by lung
macrophages and dendritic cells. Ann Am Thorac Soc. 2014;11(Suppl 5):S306–
13.
[PubMed][PubMedCentral]
126.
Danielsson R, Eriksson H. Aluminium adjuvants in vaccines – a way to
modulate the immune response. Semin Cell Dev Biol. 2021;115:3–9.
[PubMed]
127.
Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the
oldest adjuvant. J Med Microbiol. 2012;61(Pt 7):927–34.
[PubMed]
128.
Hogenesch H. Mechanism of immunopotentiation and safety of aluminum
adjuvants. Front Immunol. 2012;3:406.
[PubMed]
129.
Xu H, et al. Nasal aluminum (oxy)hydroxide enables adsorbed antigens to
induce speciic systemic and mucosal immune responses. Hum Vaccin
Immunother. 2017;13(11):2688–94.
[PubMed][PubMedCentral]
130.
Blaauboer SM, et al. The mucosal adjuvant cyclic di-GMP enhances antigen
uptake and selectively activates pinocytosis-eficient cells in vivo. elife.
2015:4:e06670.
131.
Facciola A, et al. An overview of vaccine adjuvants: current evidence and future
perspectives. Vaccines (Basel). 2022;10(5):819.
132.
Bhide Y, et al. Cross-protective potential and protection-relevant immune
mechanisms of whole inactivated inluenza virus vaccines are determined by
adjuvants and route of immunization. Front Immunol. 2019;10:646.
[PubMed][PubMedCentral]
133.
Toniolo SP, et al. Excipient selection for thermally stable enveloped and nonenveloped viral vaccine platforms in dry powders. Int J Pharm. 2019;561:66–
73.
[PubMed]
134.
Akhami S, et al. Spray dried human and chimpanzee adenoviral-vectored
vaccines are thermally stable and immunogenic in vivo. Vaccine.
2017;35(22):2916–24.
https://t.me/medicina_free
[PubMed]
135.
Toniolo SP, et al. Spray dried VSV-vectored vaccine is thermally stable and
immunologically active in vivo. Sci Rep. 2020;10(1):13349.
[PubMed][PubMedCentral]
136.
Price DN, et al. Design and optimization of a temperature-stable dry powder
BCG vaccine. Pharm Res. 2019;37(1):11.
[PubMed]
137.
LeClair DA, et al. Evaluation of excipients for enhanced thermal stabilization of
a human type 5 adenoviral vector through spray drying. Int J Pharm.
2016;506(1–2):289–301.
[PubMed]
138.
Trenkel M, Scherliess R. Optimising nasal powder drug delivery –
characterisation of the effect of excipients on drug absorption. Int J Pharm.
2023;633:122630.
[PubMed]
139.
Chaturvedi M, Kumar M, Pathak K. A review on mucoadhesive polymer used in
nasal drug delivery system. J Adv Pharm Technol Res. 2011;2(4):215–22.
[PubMed][PubMedCentral]
140.
Pu Y, et al. A comparison of the deposition patterns of different nasal spray
formulations using a nasal cast. Aerosol Sci Technol. 2014;48(9):930–8.
141.
Maaz A, Blagbrough IS, De Bank PA. In vitro evaluation of nasal aerosol
depositions: an insight for direct nose to brain drug delivery. Pharmaceutics.
2021;13(7)
142.
Foo MY, et al. The inluence of spray properties on intranasal deposition. J
Aerosol Med. 2007;20(4):495–508.
[PubMed]
143.
Ramvikas M, et al. Chapter ifteen – nasal vaccine delivery. In: Skwarczynski M,
Toth I, editors. Micro and nanotechnology in vaccine development. William
Andrew Publishing; 2017. p. 279–301.
144.
Jiao J, Zhang L. Inluence of intranasal drugs on human nasal mucociliary
clearance and ciliary beat frequency. Allergy Asthma Immunol Res.
2019;11(3):306–19.
[PubMed]
https://t.me/medicina_free
145.
Merkus FW, et al. Nasal mucociliary clearance as a factor in nasal drug delivery.
Adv Drug Deliv Rev. 1998;29(1–2):13–38.
[PubMed]
146.
Merkus P, et al. Inluence of anatomy and head position on intranasal drug
deposition. Eur Arch Otorhinolaryngol. 2006;263(9):827–32.
[PubMed]
147.
Anderson P. Use of respimat soft mist inhaler in COPD patients. Int J Chron
Obstruct Pulmon Dis. 2006;1(3):251–9.
[PubMed][PubMedCentral]
148.
Manjaly Thomas ZR, et al. Alternate aerosol and systemic immunisation with a
recombinant viral vector for tuberculosis, MVA85A: a phase I randomised
controlled trial. PLoS Med. 2019;16(4):e1002790.
[PubMed][PubMedCentral]
149.
Low N, et al. A randomized, controlled trial of an aerosolized vaccine against
measles. N Engl J Med. 2015;372(16):1519–29.
[PubMed]
150.
Satti I, et al. Safety and immunogenicity of a candidate tuberculosis vaccine
MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1,
double-blind, randomised controlled trial. Lancet Infect Dis. 2014;14(10):939–
46.
[PubMed][PubMedCentral]
151.
Chan VW, et al. Transmission of severe acute respiratory syndrome coronavirus
1 and severe acute respiratory syndrome coronavirus 2 during aerosolgenerating procedures in critical care: a systematic review and meta-analysis
of observational studies. Crit Care Med. 2021;49(7):1159–68.
[PubMed]
152.
Group MA, et al. Safety and immunogenicity of dry powder measles vaccine
administered by inhalation: a randomized controlled phase I clinical trial.
Vaccine. 2014;32(50):6791–7.
153.
Gregoriano C, et al. Use and inhalation technique of inhaled medication in
patients with asthma and COPD: data from a randomized controlled trial.
Respir Res. 2018;19(1):237.
[PubMed][PubMedCentral]
https://t.me/medicina_free
154.
Harb HS, et al. Determinants of incorrect inhaler technique in chronic
obstructive pulmonary disease patients. Int J Clin Pract. 2021;75(6):e14073.
[PubMed]
155.
Kaplan A, Price D. Matching inhaler devices with patients: the role of the
primary care physician. Can Respir J. 2018;2018:9473051.
[PubMed][PubMedCentral]
156.
Claus S, et al. How can we bring high drug doses to the lung? Eur J Pharm
Biopharm. 2014;86(1):1–6.
[PubMed]
157.
Scherliess R, Etschmann C. DPI formulations for high dose applications –
challenges and opportunities. Int J Pharm. 2018;548(1):49–53.
[PubMed]
158.
Son YJ, Miller DP, Weers JG. Optimizing spray-dried porous particles for high
dose delivery with a portable dry powder inhaler. Pharmaceutics.
2021;13(9):1528.
159.
Cheng YS. Mechanisms of pharmaceutical aerosol deposition in the respiratory
tract. AAPS PharmSciTech. 2014;15(3):630–40.
[PubMed][PubMedCentral]
160.
Chow MYT, et al. In vitro-in vivo correlation of cascade impactor data for
orally inhaled pharmaceutical aerosols. Adv Drug Deliv Rev. 2021;177:113952.
[PubMed]
161.
Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious
diseases: principles, delivery and clinical translation. Nat Rev Drug Discov.
2021;20(11):817–38.
[PubMed][PubMedCentral]
162.
Chalkias S, et al. A bivalent omicron-containing booster vaccine against Covid-
19. N Engl J Med. 2022;387(14):1279–91.
[PubMed]
163.
Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and
solutions. Nat Biotechnol. 2006;24(11):1377–83.
[PubMed]
164.
Wu S, et al. A single dose of an adenovirus-vectored vaccine provides
protection against SARS-CoV-2 challenge. Nat Commun. 2020;11(1):4081.
[PubMed][PubMedCentral]
https://t.me/medicina_free
165.
Rosa SS, et al. mRNA vaccines manufacturing: challenges and bottlenecks.
Vaccine. 2021;39(16):2190–200.
[PubMed][PubMedCentral]
166.
Jackson NAC, et al. The promise of mRNA vaccines: a biotech and industrial
perspective. NPJ Vaccines. 2020;5:11.
[PubMed][PubMedCentral]
167.
Saluja V, et al. A comparison between spray drying and spray freeze drying to
produce an inluenza subunit vaccine powder for inhalation. J Control Release.
2010;144(2):127–33.
[PubMed]
168.
Adali MB, et al. Spray freeze-drying as a solution to continuous manufacturing
of pharmaceutical products in bulk. PRO. 2020;8(6):709.
169.
Preston KB, Randolph TW. Stability of lyophilized and spray dried vaccine
formulations. Adv Drug Deliv Rev. 2021;171:50–61.
[PubMed]
170.
Lapuente D, et al. Protective mucosal immunity against SARS-CoV-2 after
heterologous systemic prime-mucosal boost immunization. Nat Commun.
2021;12(1):6871.
[PubMed][PubMedCentral]
171.
Chow MYT, et al. Inhalable neutralizing antibodies – promising approach to
combating respiratory viral infections. Trends Pharmacol Sci. 2023;44(2):85–
97.
[PubMed]
172.
van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat
Mater. 2020;19(8):810–2.
[PubMed]
173.
Tregoning JS, et al. Vaccines for COVID-19. Clin Exp Immunol. 2020;202(2):162–
92.
[PubMed][PubMedCentral]
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана